These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ivermectin in dermatology. del Giudice P; Chosidow O; Caumes E J Drugs Dermatol; 2003 Jan; 2(1):13-21. PubMed ID: 12852376 [TBL] [Abstract][Full Text] [Related]
23. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715 [TBL] [Abstract][Full Text] [Related]
24. [Ivermectin and tropical dermatoses]. Caumes E Bull Soc Pathol Exot; 1997; 90(1):37-8. PubMed ID: 9264749 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. Thadanipon K; Anothaisintawee T; Rattanasiri S; Thakkinstian A; Attia J J Am Acad Dermatol; 2019 May; 80(5):1435-1444. PubMed ID: 30654070 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Speich B; Ali SM; Ame SM; Bogoch II; Alles R; Huwyler J; Albonico M; Hattendorf J; Utzinger J; Keiser J Lancet Infect Dis; 2015 Mar; 15(3):277-84. PubMed ID: 25589326 [TBL] [Abstract][Full Text] [Related]
27. Mass Drug Administration for Scabies Control in a Population with Endemic Disease. Romani L; Whitfeld MJ; Koroivueta J; Kama M; Wand H; Tikoduadua L; Tuicakau M; Koroi A; Andrews R; Kaldor JM; Steer AC N Engl J Med; 2015 Dec; 373(24):2305-13. PubMed ID: 26650152 [TBL] [Abstract][Full Text] [Related]
28. The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus. Awadzi K; Edwards G; Duke BO; Opoku NO; Attah SK; Addy ET; Ardrey AE; Quartey BT Ann Trop Med Parasitol; 2003 Mar; 97(2):165-78. PubMed ID: 12803872 [TBL] [Abstract][Full Text] [Related]
29. [Ivermectin]. Boussinesq M Med Trop (Mars); 2005; 65(1):69-79. PubMed ID: 15903082 [TBL] [Abstract][Full Text] [Related]
31. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg). Kamgno J; Pion SD; Tejiokem MC; Twum-Danso NA; Thylefors B; Boussinesq M Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):777-85. PubMed ID: 17531279 [TBL] [Abstract][Full Text] [Related]
32. Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. Anto F; Asoala V; Anyorigiya T; Oduro A; Adjuik M; Akweongo P; Aborigo R; Bimi L; Amankwa J; Hodgson A Trop Med Int Health; 2011 Sep; 16(9):1112-9. PubMed ID: 21689221 [TBL] [Abstract][Full Text] [Related]
33. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Awadzi K; Dadzie KY; Shulz-Key H; Haddock DR; Gilles HM; Aziz MA Ann Trop Med Parasitol; 1985 Feb; 79(1):63-78. PubMed ID: 3838638 [TBL] [Abstract][Full Text] [Related]
34. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Chaccour C; Hammann F; Rabinovich NR Malar J; 2017 Apr; 16(1):161. PubMed ID: 28434401 [TBL] [Abstract][Full Text] [Related]
35. Factors affecting adverse event reporting during mass ivermectin treatment for onchocerciasis. Chijioke CP Acta Trop; 2000 Sep; 76(2):169-73. PubMed ID: 10936576 [TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Chhaiya SB; Patel VJ; Dave JN; Mehta DS; Shah HA Indian J Dermatol Venereol Leprol; 2012; 78(5):605-10. PubMed ID: 22960817 [TBL] [Abstract][Full Text] [Related]
38. High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug. Chosidow O; Bernigaud C; Do-Pham G Parasite; 2018; 25():33. PubMed ID: 30016258 [TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results. Fobi G; Gardon J; Kamgno J; Aimard-Favennec L; Lafleur C; Gardon-Wendel N; Duke BO; Boussinesq M Trans R Soc Trop Med Hyg; 2005 Apr; 99(4):279-89. PubMed ID: 15708387 [TBL] [Abstract][Full Text] [Related]
40. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. Brooks PA; Grace RF J Paediatr Child Health; 2002 Aug; 38(4):401-4. PubMed ID: 12174005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]